The journey of a disease-modifying osteoarthritis drug: From research to reality

Joint Action

内容由David Hunter and FRACP (Rheum)提供。所有播客内容（包括剧集、图形和播客描述）均由 David Hunter and FRACP (Rheum) 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

2M ago 37:57

MP3•单集首页

In this week's episode, we explore the quest for a therapy that not only alleviates symptoms of osteoarthritis but also addresses the underlying disease process. Host Professor David Hunter is joined by Chris Knight and Dr Sandeep Basnet from Formation Bio to discuss the complexities and breakthroughs in developing disease-modifying osteoarthritis drugs (DMOADs).

They dive into the challenges of clinical trials, the high stakes of drug development, and the promising future of AI in revolutionising this field.

Tune in to learn how close we are to seeing these game-changing therapies become a reality and what it could mean for millions living with osteoarthritis.

RESOURCES

Formation Bio: https://www.formation.bio/

CONNECT WITH US

Twitter/X: @ProfDavidHunter @jointactionorg
Instagram: @ProfDavidHunter
Email: hello@jointaction.info

Hosted on Acast. See acast.com/privacy for more information.

130集单集

#Fitness #Medicine #David Hunter #FRACP (Rheum #Osteoarthritis #Arthritis #Rheumatology #Physiotherapy #Exercise #Aging #Medicines For Osteoarthritis #Exercises For Osteoarthritis #Opioids And Osteoarthritis #Supplements For Osteoarthritis